Allurion Technologies (ALUR) Scheduled to Post Earnings on Wednesday

Allurion Technologies (NYSE:ALUR) is set to issue its quarterly earnings data before the market opens on Wednesday, November 13th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

Allurion Technologies (NYSE:ALUR) last issued its quarterly earnings results on Tuesday, August 13th. The company reported $0.01 EPS for the quarter. The business had revenue of $11.77 million for the quarter. On average, analysts expect Allurion Technologies to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Allurion Technologies Stock Performance

Shares of ALUR opened at $0.72 on Tuesday. The firm has a market capitalization of $46.58 million, a price-to-earnings ratio of -0.82 and a beta of -0.37. Allurion Technologies has a one year low of $0.55 and a one year high of $4.64. The stock’s fifty day moving average is $0.68 and its 200-day moving average is $1.07.

Analyst Upgrades and Downgrades

ALUR has been the topic of a number of research analyst reports. Chardan Capital lowered their price target on Allurion Technologies from $5.00 to $2.50 and set a “buy” rating on the stock in a report on Thursday, August 22nd. Roth Capital raised Allurion Technologies to a “strong-buy” rating in a report on Friday, September 6th. TD Cowen began coverage on Allurion Technologies in a report on Wednesday, October 2nd. They set a “buy” rating and a $2.00 target price on the stock. Finally, Roth Mkm began coverage on Allurion Technologies in a report on Friday, September 6th. They set a “buy” rating and a $2.00 target price on the stock. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $2.88.

Allurion Technologies Company Profile

Allurion Technologies Inc focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite.